May 29, 2018
Authored and Edited by M. David Weingarten, Ph.D.; Thomas L. Irving
On May 21, 2018, FDA issued final guidance on Bioanalytical Method Validation. The guidance incorporates public comments to the revised draft published in 2013, which followed an initial release of guidance in 2001, and reflects advances in science and technology. The guidance describes the elements of bioanalytical method development and validation that are needed to ensure the quality of an assay and the reliability of the data it generates.
The guidance is meant to help when validating bioanalytical methods used in human clinical pharmacology, bioavailability, and bioequivalence studies and applies to bioanalytical procedures such as chromatographic assays and ligand binding assays that quantitatively determine the levels of drugs, their metabolites, therapeutic proteins, and biomarkers in biological matrices such as blood, serum, plasma, urine, and tissue such as skin. The guidance may also inform the development of bioanalytical methods used for certain nonclinical studies.
Before the development of a bioanalytical method, FDA recommends the sponsor understand the analyte of interest (e.g. the physiochemical properties, metabolism, binding) and consider aspects of any prior analytical methods that may be applicable. The sponsor should then optimize the procedures and conditions involved with extracting and detecting analyte with an emphasis on certain bioanalytical parameters, such as references standards, critical reagents, calibration curve, quality control samples, selectivity and specificity, sensitivity, accuracy, precision, recovery, and stability.
FDA also identifies recommended steps for bioanalytical method validation. Specifically, the sponsor should:
The elements and acceptance criteria of method development and validation are summarized in Table 1 of the guidance. Recommended documentation for method validation and bioanalytical reports are specifically described in Table 2.
Readers are encouraged to read the final guidance, also available on FDA’s website.
drugs, Food and Drug Administration (FDA), FDA Guidance, Biologic License Application (BLA), new drug application (NDA), 2018 Top Insights
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
INCONTESTABLE® Blog
April 19, 2024
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in February 2024
April 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.